{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:33:15Z","timestamp":1751369595638,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10067-022-06199-8","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T22:02:35Z","timestamp":1654725755000},"page":"3005-3016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3606-3949","authenticated-orcid":false,"given":"Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2125-570X","authenticated-orcid":false,"given":"Zhixin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0632-9195","authenticated-orcid":false,"given":"Zhenbiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7889-0398","authenticated-orcid":false,"given":"Liqi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-4535","authenticated-orcid":false,"given":"Huaxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6466-2770","authenticated-orcid":false,"given":"Lijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-1705","authenticated-orcid":false,"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4723-0412","authenticated-orcid":false,"given":"Xiangyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-9690","authenticated-orcid":false,"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-9623","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-3934","authenticated-orcid":false,"given":"Wufang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-3250","authenticated-orcid":false,"given":"Lan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-8889","authenticated-orcid":false,"given":"Lie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8563-2036","authenticated-orcid":false,"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-2596","authenticated-orcid":false,"given":"Xiaomei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4657-1103","authenticated-orcid":false,"given":"Zongwen","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0000-3792","authenticated-orcid":false,"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-456X","authenticated-orcid":false,"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-561X","authenticated-orcid":false,"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-3485","authenticated-orcid":false,"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-6673","authenticated-orcid":false,"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5183-1029","authenticated-orcid":false,"given":"Xiaoxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0466-1872","authenticated-orcid":false,"given":"Chunde","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"10089","key":"6199_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4","journal-title":"Lancet"},{"issue":"26","key":"6199_CR2","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563\u20132574. https:\/\/doi.org\/10.1056\/NEJMra1406182","journal-title":"N Engl J Med"},{"issue":"7","key":"6199_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3760\/cma.j.cn112138-20200505-00448","volume":"59","author":"G Jieruo","year":"2020","unstructured":"Jieruo G, Xie Y, Kehu Y, Qing L, Yi Z, Cibo H et al (2020) Practice guideline for patients with ankylosing spondylitis\/spondyloarthritis. Zhonghua Nei Ke Za Zhi 59(7):511\u2013518. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20200505-00448","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"5","key":"6199_CR4","first-page":"661","volume":"32","author":"T Liudan","year":"2014","unstructured":"Liudan T, Rai JC, Cao S, Lin Z, Hu Z, Gu J (2014) Costs and work limitation of patients with ankylosing spondylitis in China. Clin Exp Rheumatol 32(5):661\u2013666","journal-title":"Clin Exp Rheumatol"},{"key":"6199_CR5","doi-asserted-by":"publisher","first-page":"m4447","DOI":"10.1136\/bmj.m4447","volume":"372","author":"C Ritchlin","year":"2021","unstructured":"Ritchlin C, Adamopoulos IE (2021) Axial spondyloarthritis: new advances in diagnosis and management. BMJ 372:m4447. https:\/\/doi.org\/10.1136\/bmj.m4447","journal-title":"BMJ"},{"key":"6199_CR6","doi-asserted-by":"publisher","first-page":"2171475","DOI":"10.1155\/2019\/2171475","volume":"2019","author":"X Ji","year":"2019","unstructured":"Ji X, Wang Y, Ma Y, Hu Z, Man S, Zhang Y, Li K, Yang J, Zhu J, Zhang J, Huang F (2019) Improvement of disease management and cost effectiveness in chinese patients with ankylosing spondylitis using a smart-phone management system: a prospective cohort study. Biomed Res Int 2019:2171475. https:\/\/doi.org\/10.1155\/2019\/2171475","journal-title":"Biomed Res Int"},{"issue":"10","key":"6199_CR7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D et al (2019) Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 71(10):1285\u20131299. https:\/\/doi.org\/10.1002\/art.41042","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"6199_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11882-014-0489-6","volume":"15","author":"JA Smith","year":"2015","unstructured":"Smith JA (2015) Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 15(1):489. https:\/\/doi.org\/10.1007\/s11882-014-0489-6","journal-title":"Curr Allergy Asthma Rep"},{"key":"6199_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","volume":"101","author":"H Mitoma","year":"2018","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H, Ueda N (2018) Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists. Cytokine 101:56\u201363. https:\/\/doi.org\/10.1016\/j.cyto.2016.08.014","journal-title":"Cytokine"},{"key":"6199_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/OARRR.S44550","volume":"6","author":"A Mounach","year":"2014","unstructured":"Mounach A, El Maghraoui A (2014) Efficacy and safety of adalimumab in ankylosing spondylitis. Open Access Rheumatol 6:83\u201390. https:\/\/doi.org\/10.2147\/OARRR.S44550","journal-title":"Open Access Rheumatol"},{"issue":"4","key":"6199_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J et al (2009) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36(4):801\u2013808. https:\/\/doi.org\/10.3899\/jrheum.081048","journal-title":"J Rheumatol"},{"issue":"7","key":"6199_CR12","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/rheumatology\/keu438","volume":"54","author":"D van der Heijde","year":"2015","unstructured":"van der Heijde D, Breban M, Halter D, DiVittorio G, Bratt J et al (2015) Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology (Oxford) 54(7):1210\u20131219. https:\/\/doi.org\/10.1093\/rheumatology\/keu438","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"6199_CR13","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136\u20132146. https:\/\/doi.org\/10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"issue":"3","key":"6199_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2014","unstructured":"Huang F, Jieruo G, Zhu P, Bao C, Xu J, Xu H, Wu H et al (2014) Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 73(3):587\u2013594. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202533","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"6199_CR15","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","volume":"76","author":"E Lie","year":"2017","unstructured":"Lie E, Lindstr\u00f6m U, Zverkova-Sandstr\u00f6m T, Olsen IC, Forsblad-d\u2019Elia H et al (2017) Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 76(9):1515\u20131521. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210931","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6199_CR16","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3111\/13696998.2012.692341","volume":"15","author":"X Gao","year":"2012","unstructured":"Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M (2012) Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ 15(6):1054\u20131063. https:\/\/doi.org\/10.3111\/13696998.2012.692341","journal-title":"J Med Econ"},{"issue":"5","key":"6199_CR17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, R\u00f8devand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696\u2013701. https:\/\/doi.org\/10.1136\/ard.2008.092585","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6199_CR18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A et al (2017) Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis 76(10):1679\u20131687. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210459","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6199_CR19","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/13543784.2016.1255724","volume":"25","author":"C Wynne","year":"2016","unstructured":"Wynne C, Altendorfer M, Sonderegger I, Gheyle L, Ellis-Pegler R et al (2016) Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE(R)-PK) in healthy subjects. Expert Opin Investig Drugs 25(12):1361\u20131370. https:\/\/doi.org\/10.1080\/13543784.2016.1255724","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"6199_CR20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cpt.2322","volume":"110","author":"CWC Lee","year":"2021","unstructured":"Lee CWC, Najafzadeh M, Kesselheim AS, Sarpatwari A (2021 Oct) Cost to medicare of delayed adalimumab biosimilar availability. Clin Pharmacol Ther 110(4):1050\u20131056. https:\/\/doi.org\/10.1002\/cpt.2322","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"6199_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3760\/cma.j.cn115356-20210117-00018","volume":"30","author":"J Ma","year":"2021","unstructured":"Ma J et al (2021) Expert consensus on the clinical application of biosimilars. Zhonghua Xue Ye Xue Za Zhi 30(3):129\u2013136. https:\/\/doi.org\/10.3760\/cma.j.cn115356-20210117-00018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"6199_CR22","doi-asserted-by":"publisher","unstructured":"Wang Y, Gao Z, Liu Z, Liu G, Xinyao Q, Chen J, Ren X, Xu Z, Yang H (2021) A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira(R) in healthy Chinese male volunteers. Expert Opin Biol Ther:1\u201310. https:\/\/doi.org\/10.1080\/14712598.2021.1944097","DOI":"10.1080\/14712598.2021.1944097"},{"issue":"11","key":"6199_CR23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3760\/cma.j.issn.0578-1426.2009.11.007","volume":"48","author":"F Huang","year":"2009","unstructured":"Huang F, Zhang F-C, Bao C-d, Tao Y, Jie-Ruo G et al (2009) Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study. Zhonghua Nei Ke Za Zhi 48(11):916\u2013921. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1426.2009.11.007","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"6199_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jdv.13746","volume":"31","author":"L Cai","year":"2017","unstructured":"Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi L-Y et al (2017) Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol 31(1):89\u201395. https:\/\/doi.org\/10.1111\/jdv.13746","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"6199_CR25","doi-asserted-by":"publisher","first-page":"175628482093896","DOI":"10.1177\/1756284820938960","volume":"13","author":"B Chen","year":"2020","unstructured":"Chen B, Gao X, Zhong J, Ren J, Zhu X et al (2020) Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn\u2019s disease: results from a randomized trial. Therap Adv Gastroenterol 13:1756284820938960. https:\/\/doi.org\/10.1177\/1756284820938960","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"6199_CR26","first-page":"836","volume":"36","author":"C Yu","year":"2018","unstructured":"Yu C, Li M, Duan X, Fang Y, Li Q et al (2018) Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis. Clin Exp Rheumatol 36(5):836\u2013840","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"6199_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40259-020-00408-z","volume":"34","author":"S Jinmei","year":"2020","unstructured":"Jinmei S, Li M, He L, Zhao D, Wan W et al (2020) Comparison of the efficacy and safety of adalimumab (Humira) and the adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis: a multicenter, randomized, double-Blind, parallel, phase III clinical trial. BioDrugs 34(3):381\u2013393. https:\/\/doi.org\/10.1007\/s40259-020-00408-z","journal-title":"BioDrugs"},{"issue":"9","key":"6199_CR28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","volume":"48","author":"D Elewaut","year":"2009","unstructured":"Elewaut D, Matucci-Cerinic M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 48(9):1029\u20131035. https:\/\/doi.org\/10.1093\/rheumatology\/kep146","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"6199_CR29","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/apt.13994","volume":"45","author":"AS Strik","year":"2017","unstructured":"Strik AS, van den Brink GR, Ponsioen C, Mathot R, L\u00f6wenberg M, D'Haens GR (2017) Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther 45(8):1128\u20131134. https:\/\/doi.org\/10.1111\/apt.13994","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"6199_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-019-1857-3","volume":"21","author":"S Cohen","year":"2019","unstructured":"Cohen S, Pablos JL, Pavelka K, M\u00fcller GA, Matsumoto A, Kivitz A, Wang H, Krishnan E (2019) An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. Arthritis Res Ther 21(1):84. https:\/\/doi.org\/10.1186\/s13075-019-1857-3","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"6199_CR31","doi-asserted-by":"publisher","first-page":"e000987","DOI":"10.1136\/rmdopen-2019-000987","volume":"6","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Kellner H, Arai Y, Muniz R, Alten R (2020) Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD Open 6(1):e000987. https:\/\/doi.org\/10.1136\/rmdopen-2019-000987","journal-title":"RMD Open"},{"issue":"6","key":"6199_CR32","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/art.40444","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J et al (2018) Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. Arthritis Rheumatol 70(6):832\u2013840. https:\/\/doi.org\/10.1002\/art.40444","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"6199_CR33","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/annrheumdis-2017-212245","volume":"77","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Alonso-Ruiz A, Klimiuk PA, Lee EC, Peter N, Sonderegger I, Assudani D (2018) Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis 77(6):914\u2013921. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212245","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06199-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06199-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06199-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T14:27:36Z","timestamp":1663597656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06199-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["6199"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06199-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations\u00a0"}},{"value":"This study was conducted in accordance with Good Clinical Practice and Declaration of Helsinki. The study protocol was approved by the ethics committee of Renji Hospital, Shanghai Jiao Tong University School of medicine (RJLS2018-089) on Sep.7<sup>th<\/sup>,2018. All patients provided written Informed consent. The registration number of this study in the Chinese Clinical Trial Registry is CTR20181863.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}